Saturday, October 24, 2026RSS
Peptide.Wire

The daily wire on therapeutic peptides. Regulatory, research, compounding and the incretin race, condensed.

GLP-1semaglutideantipsychotic-induced weight gainpediatricsaripiprazole

Case report describes semaglutide stopped after antipsychotic weight gain reversed

The adolescent kept the weight off and maintained normal hemoglobin A1c through six months off the drug, the authors report.

MH
By Maren Holt · Senior Reporter, GLP-1
Oct 11 20:00 ETSource: Hormone research in paediatrics

The wire

  1. 01A single adolescent case in Hormone Research in Paediatrics: semaglutide normalized BMI and hemoglobin A1c after aripiprazole-induced weight gain, then was discontinued with weight maintained over six months.
  2. 02Pediatric clinicians managing antipsychotic-induced weight gain currently lean on metformin, which the authors call modestly effective; the report raises GLP-1 agonists as possible temporary bridge therapy.
  3. 03The authors call the observation hypothesis-generating only, citing confounding factors, and say larger prospective studies are needed before any broader clinical use.

From the source

Weight Maintenance Following Discontinuation of Semaglutide in an Adolescent with Antipsychotic-Associated Weight Gain: A Case Report

Hormone research in paediatrics · 2026 Oct 12 · Griffing E, Dabrowski E et al.

Read at pubmed.ncbi.nlm.nih.gov
PeptiPrescribed peptides from $99/moSee all →